These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1621 related articles for article (PubMed ID: 24078774)

  • 1. Activation of the PD-1 pathway contributes to immune escape in EGFR-driven lung tumors.
    Akbay EA; Koyama S; Carretero J; Altabef A; Tchaicha JH; Christensen CL; Mikse OR; Cherniack AD; Beauchamp EM; Pugh TJ; Wilkerson MD; Fecci PE; Butaney M; Reibel JB; Soucheray M; Cohoon TJ; Janne PA; Meyerson M; Hayes DN; Shapiro GI; Shimamura T; Sholl LM; Rodig SJ; Freeman GJ; Hammerman PS; Dranoff G; Wong KK
    Cancer Discov; 2013 Dec; 3(12):1355-63. PubMed ID: 24078774
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dynamic interplay of oncogenes and T cells induces PD-L1 in the tumor microenvironment.
    Rech AJ; Vonderheide RH
    Cancer Discov; 2013 Dec; 3(12):1330-2. PubMed ID: 24327693
    [TBL] [Abstract][Full Text] [Related]  

  • 3. ILT4 inhibition prevents TAM- and dysfunctional T cell-mediated immunosuppression and enhances the efficacy of anti-PD-L1 therapy in NSCLC with EGFR activation.
    Chen X; Gao A; Zhang F; Yang Z; Wang S; Fang Y; Li J; Wang J; Shi W; Wang L; Zheng Y; Sun Y
    Theranostics; 2021; 11(7):3392-3416. PubMed ID: 33537094
    [No Abstract]   [Full Text] [Related]  

  • 4. A Small Molecule Antagonist of PD-1/PD-L1 Interactions Acts as an Immune Checkpoint Inhibitor for NSCLC and Melanoma Immunotherapy.
    Wang Y; Gu T; Tian X; Li W; Zhao R; Yang W; Gao Q; Li T; Shim JH; Zhang C; Liu K; Lee MH
    Front Immunol; 2021; 12():654463. PubMed ID: 34054817
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Upregulation of PD-L1 by EGFR Activation Mediates the Immune Escape in EGFR-Driven NSCLC: Implication for Optional Immune Targeted Therapy for NSCLC Patients with EGFR Mutation.
    Chen N; Fang W; Zhan J; Hong S; Tang Y; Kang S; Zhang Y; He X; Zhou T; Qin T; Huang Y; Yi X; Zhang L
    J Thorac Oncol; 2015 Jun; 10(6):910-23. PubMed ID: 25658629
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Epidermal Growth Factor Receptor (EGFR) Pathway, Yes-Associated Protein (YAP) and the Regulation of Programmed Death-Ligand 1 (PD-L1) in Non-Small Cell Lung Cancer (NSCLC).
    Hsu PC; Jablons DM; Yang CT; You L
    Int J Mol Sci; 2019 Aug; 20(15):. PubMed ID: 31387256
    [TBL] [Abstract][Full Text] [Related]  

  • 7. EGFR-TKI resistance promotes immune escape in lung cancer via increased PD-L1 expression.
    Peng S; Wang R; Zhang X; Ma Y; Zhong L; Li K; Nishiyama A; Arai S; Yano S; Wang W
    Mol Cancer; 2019 Nov; 18(1):165. PubMed ID: 31747941
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Morphine-3-glucuronide upregulates PD-L1 expression
    Wang K; Wang J; Liu T; Yu W; Dong N; Zhang C; Xia W; Wei F; Yang L; Ren X
    Cancer Biol Med; 2021 Feb; 18(1):155-171. PubMed ID: 33628591
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immune Marker Profiling and Programmed Death Ligand 1 Expression Across NSCLC Mutations.
    Toki MI; Mani N; Smithy JW; Liu Y; Altan M; Wasserman B; Tuktamyshov R; Schalper K; Syrigos KN; Rimm DL
    J Thorac Oncol; 2018 Dec; 13(12):1884-1896. PubMed ID: 30267840
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intrinsic and Extrinsic Regulation of PD-L2 Expression in Oncogene-Driven Non-Small Cell Lung Cancer.
    Shibahara D; Tanaka K; Iwama E; Kubo N; Ota K; Azuma K; Harada T; Fujita J; Nakanishi Y; Okamoto I
    J Thorac Oncol; 2018 Jul; 13(7):926-937. PubMed ID: 29596910
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Liver fibrosis promotes immune escape in hepatocellular carcinoma via GOLM1-mediated PD-L1 upregulation.
    Ke MY; Xu T; Fang Y; Ye YP; Li ZJ; Ren FG; Lu SY; Zhang XF; Wu RQ; Lv Y; Dong J
    Cancer Lett; 2021 Aug; 513():14-25. PubMed ID: 33992711
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Continuous targeted kinase inhibitors treatment induces upregulation of PD-L1 in resistant NSCLC.
    Jiang L; Guo F; Liu X; Li X; Qin Q; Shu P; Li Y; Wang Y
    Sci Rep; 2019 Mar; 9(1):3705. PubMed ID: 30842489
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The canonical TGF-β/Smad signalling pathway is involved in PD-L1-induced primary resistance to EGFR-TKIs in EGFR-mutant non-small-cell lung cancer.
    Zhang Y; Zeng Y; Liu T; Du W; Zhu J; Liu Z; Huang JA
    Respir Res; 2019 Jul; 20(1):164. PubMed ID: 31331328
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tumour cell-intrinsic CTLA4 regulates PD-L1 expression in non-small cell lung cancer.
    Zhang H; Dutta P; Liu J; Sabri N; Song Y; Li WX; Li J
    J Cell Mol Med; 2019 Jan; 23(1):535-542. PubMed ID: 30378264
    [TBL] [Abstract][Full Text] [Related]  

  • 15. EGFR mutations induce the suppression of CD8
    Huang H; Zhu X; Yu Y; Li Z; Yang Y; Xia L; Lu S
    J Transl Med; 2024 Jul; 22(1):653. PubMed ID: 39004699
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PD-L1 expression and T cells infiltration in patients with uncommon EGFR-mutant non-small cell lung cancer and the response to immunotherapy.
    Chen K; Cheng G; Zhang F; Zhu G; Xu Y; Yu X; Huang Z; Fan Y
    Lung Cancer; 2020 Apr; 142():98-105. PubMed ID: 32120230
    [TBL] [Abstract][Full Text] [Related]  

  • 17. EGFR Mutations and ALK Rearrangements Are Associated with Low Response Rates to PD-1 Pathway Blockade in Non-Small Cell Lung Cancer: A Retrospective Analysis.
    Gainor JF; Shaw AT; Sequist LV; Fu X; Azzoli CG; Piotrowska Z; Huynh TG; Zhao L; Fulton L; Schultz KR; Howe E; Farago AF; Sullivan RJ; Stone JR; Digumarthy S; Moran T; Hata AN; Yagi Y; Yeap BY; Engelman JA; Mino-Kenudson M
    Clin Cancer Res; 2016 Sep; 22(18):4585-93. PubMed ID: 27225694
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Membrane-Associated RING-CH 8 Functions as a Novel PD-L1 E3 Ligase to Mediate PD-L1 Degradation Induced by EGFR Inhibitors.
    Qian G; Guo J; Vallega KA; Hu C; Chen Z; Deng Y; Wang Q; Fan S; Ramalingam SS; Owonikoko TK; Wei W; Sun SY
    Mol Cancer Res; 2021 Oct; 19(10):1622-1634. PubMed ID: 34183449
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Brain Metastasis from EGFR-Mutated Non-Small Cell Lung Cancer: Secretion of IL11 from Astrocytes Up-Regulates PDL1 and Promotes Immune Escape.
    Tang M; Xu M; Wang J; Liu Y; Liang K; Jin Y; Duan W; Xia S; Li G; Chu H; Liu W; Wang Q
    Adv Sci (Weinh); 2024 Jul; 11(26):e2306348. PubMed ID: 38696655
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Interactions between EGFR and PD-1/PD-L1 pathway: Implications for treatment of NSCLC.
    Li X; Lian Z; Wang S; Xing L; Yu J
    Cancer Lett; 2018 Apr; 418():1-9. PubMed ID: 29309815
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 82.